Literature DB >> 22228595

CHM/REP1 cDNA delivery by lentiviral vectors provides functional expression of the transgene in the retinal pigment epithelium of choroideremia mice.

Tanya Tolmachova1, Oleg E Tolmachov, Silene T Wavre-Shapton, Dhani Tracey-White, Clare E Futter, Miguel C Seabra.   

Abstract

BACKGROUND: Choroideremia (CHM) is a progressive X-linked degeneration of three ocular layers: photoreceptors, retinal pigment epithelium (RPE) and choroid, caused by the loss of Rab Escort Protein-1 (REP1). As a recessive monogenic disorder, CHM is potentially curable by gene addition therapy. The present study aimed to evaluate the potential use of lentiviral vectors carrying CHM/REP1 cDNA transgene for CHM treatment.
METHODS: We generated lentiviral vectors carrying either CHM/REP1 cDNA or EGFP transgene under the control of the elongation factor-1α promoter (EF-1α) or its shortened version EFS. We transduced human (HT1080) and dog (D17) cells, CHM patient's fibroblasts and mouse primary RPE cells in vitro, as well as wild-type and CHM mouse retinas in vivo by subretinal injections. Transgene expression was confirmed by immunoblotting, fluorescence-activated cell sorting, immunofluorescence and confocal microscopy. CHM/REP1 transgene functionality was assessed by an in vitro prenylation assay.
RESULTS: Lentiviral vectors with CHM/REP1 and EGFP transgenes efficiently transduced HT1080, D17 and CHM fibroblast cells; CHM/REP1 transgene lead to an increase in prenylation activity. Subretinal injections of lentiviral vectors into mouse retinas resulted in efficient transduction of the RPE (30-35% of total RPE cells transduced after a 1-µl injection), long-term expression for at least 6  months and a decrease in amount of unprenylated Rabs in the CHM RPE. Transduction of neuroretinal cells was restricted to the injection site.
CONCLUSIONS: Lentiviral CHM/REP1 cDNA transgene rescues the prenylation defect in CHM mouse RPE and thus could be used to restore REP1 activity in the RPE of CHM patients.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228595     DOI: 10.1002/jgm.1652

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  19 in total

1.  Scientific side trips: six excursions from the beaten path.

Authors:  Michael S Brown; Joseph L Goldstein
Journal:  J Biol Chem       Date:  2012-05-14       Impact factor: 5.157

2.  Clinical utility gene card for: choroideremia.

Authors:  Mariya Moosajee; Simon C Ramsden; Graeme C M Black; Miguel C Seabra; Andrew R Webster
Journal:  Eur J Hum Genet       Date:  2013-08-21       Impact factor: 4.246

Review 3.  A comprehensive review of retinal gene therapy.

Authors:  Shannon E Boye; Sanford L Boye; Alfred S Lewin; William W Hauswirth
Journal:  Mol Ther       Date:  2013-01-29       Impact factor: 11.454

4.  Thrombospondin-1 inhibits ossification of tissue engineered cartilage constructed by ADSCs.

Authors:  Aiguo Xie; Jixin Xue; Gan Shen; Lanjun Nie
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

Review 5.  Non-viral therapeutic approaches to ocular diseases: An overview and future directions.

Authors:  Rahel Zulliger; Shannon M Conley; Muna I Naash
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776

6.  Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease.

Authors:  William A Beltran; Artur V Cideciyan; Simone Iwabe; Malgorzata Swider; Mychajlo S Kosyk; Kendra McDaid; Inna Martynyuk; Gui-Shuang Ying; James Shaffer; Wen-Tao Deng; Sanford L Boye; Alfred S Lewin; William W Hauswirth; Samuel G Jacobson; Gustavo D Aguirre
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

Review 7.  Consequences of Rab GTPase dysfunction in genetic or acquired human diseases.

Authors:  Marcellus J Banworth; Guangpu Li
Journal:  Small GTPases       Date:  2017-12-28

Review 8.  Clinical characteristics and current therapies for inherited retinal degenerations.

Authors:  José-Alain Sahel; Katia Marazova; Isabelle Audo
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-16       Impact factor: 6.915

Review 9.  Vector platforms for gene therapy of inherited retinopathies.

Authors:  Ivana Trapani; Agostina Puppo; Alberto Auricchio
Journal:  Prog Retin Eye Res       Date:  2014-08-12       Impact factor: 21.198

10.  AAV-mediated gene therapy for choroideremia: preclinical studies in personalized models.

Authors:  Vidyullatha Vasireddy; Jason A Mills; Rajashekhar Gaddameedi; Etiena Basner-Tschakarjan; Monika Kohnke; Aaron D Black; Krill Alexandrov; Shangzhen Zhou; Albert M Maguire; Daniel C Chung; Helen Mac; Lisa Sullivan; Paul Gadue; Jeannette L Bennicelli; Deborah L French; Jean Bennett
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.